Format
Sort by
Items per page

Send to

Choose Destination

Best matches for ("drug-induced" OR "drug-related") AND ("adverse events" OR "side effects" OR "side-effects"):

Search results

Items: 1 to 20 of 39496

1.

Increased risk of thiopurine-related adverse events in elderly patients with IBD.

Calafat M, Mañosa M, Cañete F, Ricart E, Iglesias E, Calvo M, Rodríguez-Moranta F, Taxonera C, Nos P, Mesonero F, Martín-Arranz MD, Mínguez M, Gisbert JP, García-López S, de Francisco R, Gomollón F, Calvet X, Garcia-Planella E, Rivero M, Martínez-Cadilla J, Argüelles F, Arias L, Cimavilla M, Zabana Y, Domènech E; ENEIDA registry of GETECCU.

Aliment Pharmacol Ther. 2019 Aug 19. doi: 10.1111/apt.15458. [Epub ahead of print]

PMID:
31429097
2.

Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial.

Esteva FJ, Baranau YV, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskiy D, Pikiel J, Eniu AE, Li RK, Rusyn AV, Tiangco B, Lee SJ, Lee SY, Yu SY, Stebbing J.

Cancer Chemother Pharmacol. 2019 Aug 19. doi: 10.1007/s00280-019-03920-4. [Epub ahead of print]

PMID:
31428820
3.

A First-in-Human Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of a Novel Antifungal Drug VL-2397 in Healthy Adults.

Mammen MP, Armas D, Hughes FH, Hopkins AM, Fisher CL, Resch PA, Rusalov D, Sullivan SM, Smith LR.

Antimicrob Agents Chemother. 2019 Aug 19. pii: AAC.00969-19. doi: 10.1128/AAC.00969-19. [Epub ahead of print]

PMID:
31427299
4.

Discovery and Development of anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication.

Maeda K, Das D, Kobayakawa T, Tamamura H, Takeuchi H.

Curr Top Med Chem. 2019 Jul 12. doi: 10.2174/1568026619666190712204603. [Epub ahead of print]

PMID:
31424371
5.

Diabetic ketoacidosis with sodium-glucose cotransporter type 2 inhibitors: a case series.

McLachlan G, Keith C, Frauman A.

Med J Aust. 2019 Aug 16. doi: 10.5694/mja2.50302. [Epub ahead of print] No abstract available.

PMID:
31420875
6.

A randomized controlled dose-escalation study of SSS07, a humanized rabbit anti-human TNF alpha antibody, in healthy Chinese adults.

Wang Q, Xie X, Su F, Wang J, Chen S, Wang Q, Jiang D, Wang Y, Zhang T, Liu C, Han M, Tao T, Wu Q, Xi N, Li Z, Song H, Fang Y.

Int Immunopharmacol. 2019 Aug 12;75:105807. doi: 10.1016/j.intimp.2019.105807. [Epub ahead of print]

PMID:
31416011
7.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors.

Shitara K, Satoh T, Iwasa S, Yamaguchi K, Muro K, Komatsu Y, Nishina T, Esaki T, Hasegawa J, Kakurai Y, Kamiyama E, Nakata T, Nakamura K, Sakaki H, Hyodo I.

J Immunother Cancer. 2019 Aug 14;7(1):219. doi: 10.1186/s40425-019-0679-9.

8.

Can Generic Intravenous Levetiracetam Be Used for Acute Repetitive Convulsive Seizure or Status Epilepticus? A Randomized Controlled Trial.

Wongjirattikarn R, Sawanyawisuth K, Pranboon S, Tiamkao S, Tiamkao S.

Neurol Ther. 2019 Aug 12. doi: 10.1007/s40120-019-00150-x. [Epub ahead of print]

PMID:
31407191
9.

Correlation between lncRNA AC079767.4 variants and liver injury from antituberculosis treatment in West China.

Zhao Z, Peng W, Wu L, Ying B.

J Infect Chemother. 2019 Aug 9. pii: S1341-321X(19)30204-1. doi: 10.1016/j.jiac.2019.07.003. [Epub ahead of print]

PMID:
31405785
10.

Evaluation of infection rates with narrow versus broad-spectrum antibiotic regimens in civilian gunshot open-fracture injury.

Woolum JA, Bailey AM, Dugan A, Agrawal R, Baum RA.

Am J Emerg Med. 2019 Jul 23:158358. doi: 10.1016/j.ajem.2019.158358. [Epub ahead of print]

PMID:
31402235
11.

Antiepileptic drug-induced psychosis associated with MTHFR C677T: a case report.

Shimura M, Yamada H, Takahashi H, Yamada N, Go S, Yamanaka G, Kawashima H.

J Med Case Rep. 2019 Aug 12;13(1):250. doi: 10.1186/s13256-019-2188-3.

12.

Once- vs Twice-Daily Tacrolimus: Survival Rates and Side Effects: Single-Center Experience.

Turunc V, Ari E, Guven B, Tabendeh B, Yildiz A.

Transplant Proc. 2019 Aug 7. pii: S0041-1345(18)31842-6. doi: 10.1016/j.transproceed.2019.01.149. [Epub ahead of print]

PMID:
31400977
13.

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.

Motsch J, Murta de Oliveira C, Stus V, Köksal I, Lyulko O, Boucher HW, Kaye KS, File TM, Brown ML, Khan I, Du J, Joeng HK, Tipping RW, Aggrey A, Young K, Kartsonis NA, Butterton JR, Paschke A.

Clin Infect Dis. 2019 Aug 10. pii: ciz530. doi: 10.1093/cid/ciz530. [Epub ahead of print]

PMID:
31400759
14.

Conventional formulations, Challenges and Nanomedicines in Infective and Non-Infective Skin Diseases Therapy.

Rahman M, Beg S, Akhter S.

Recent Pat Antiinfect Drug Discov. 2019 Aug 9. doi: 10.2174/1574891X14666190809115503. [Epub ahead of print]

PMID:
31400272
15.

Relationship of clinical adverse event reports to models of arrhythmia risk.

Ether N, Leishman D, Bailie M, Lauver DA.

J Pharmacol Toxicol Methods. 2019 Aug 6:106622. doi: 10.1016/j.vascn.2019.106622. [Epub ahead of print]

PMID:
31398384
16.

Immunogenicity of pembrolizumab in patients with advanced tumors.

van Vugt MJH, Stone JA, De Greef RHJMM, Snyder ES, Lipka L, Turner DC, Chain A, Lala M, Li M, Robey SH, Kondic AG, De Alwis D, Mayawala K, Jain L, Freshwater T.

J Immunother Cancer. 2019 Aug 8;7(1):212. doi: 10.1186/s40425-019-0663-4.

17.

Potential hepatoxicity risk of the shell of Herpetospermum caudigerum Wall in rats based on 1H-NMR metabonomics.

Feng X, Xu H, Chen JF, Ruan LY, Zhao WL, Meng HH, Liu WY, Zhao WL, Zheng Q, Liu ZC, Kan ZB, Zhong GJ, Wang JS.

J Pharm Biomed Anal. 2019 Aug 1;176:112800. doi: 10.1016/j.jpba.2019.112800. [Epub ahead of print]

PMID:
31394304
18.

Dandelion Root and Lemongrass Extracts Induce Apoptosis, Enhance Chemotherapeutic Efficacy, and Reduce Tumour Xenograft Growth In Vivo in Prostate Cancer.

Nguyen C, Mehaidli A, Baskaran K, Grewal S, Pupulin A, Ruvinov I, Scaria B, Parashar K, Vegh C, Pandey S.

Evid Based Complement Alternat Med. 2019 Jul 17;2019:2951428. doi: 10.1155/2019/2951428. eCollection 2019.

19.

Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext).

Cohen SB, Czeloth N, Lee E, Klimiuk PA, Peter N, Jayadeva G.

Expert Opin Biol Ther. 2019 Aug 6:1-9. doi: 10.1080/14712598.2019.1645114. [Epub ahead of print]

PMID:
31387417
20.

Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma.

Sandhu S, McNeil CM, LoRusso P, Patel MR, Kabbarah O, Li C, Sanabria S, Flanagan WM, Yeh RF, Brunstein F, Nazzal D, Hicks R, Lemahieu V, Meng R, Hamid O, Infante JR.

Invest New Drugs. 2019 Aug 5. doi: 10.1007/s10637-019-00832-1. [Epub ahead of print]

PMID:
31385109

Supplemental Content

Loading ...
Support Center